Loading
IT
IRulya Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 03 Sept 2024.
IRulya Therapeutics Inc.: what insiders have been doing
IRulya Therapeutics Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 3 insiders have disclosed 4 filings since 18 October 2025.
The flow runs one way only: 1 sale worth €147k, from 1 insider, and no purchase. Benatti Luca filed the largest sale, €147k, on 29 December 2025.
With 4 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2021, counts 13 purchases against 4 sales.
Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
52
Thresholds
n/a
Buy Volume
€578,266
13 ops. · all time
Sell Volume
€535,780
4 ops. · all time
Who traded when
BuySaleLuca Benatti1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
Income statement
Net income-US$72.3M
Last declaration on 29 December 2025
Declarations52 total
50,000 shares@ US$3.47100.0% of flowCommon StockSEC:0000912282-25-001469:0
8,918 sharesCommon StockSEC:0000912282-25-001468:0
2,271 shares@ US$0.550.7% of flowCommon SharesSEC:0000912282-25-001370:0
37,736 shares@ US$1.2026.3% of flowCommon SharesSEC:0000912282-25-000697:0
7,548 shares@ US$1.2021.8% of flowCommon SharesSEC:0000912282-25-000696:0
48,387 shares@ US$0.6578.2% of flowCommon StockSEC:0001415889-24-022054:0
Canonical exit: 18 Nov 2024 (T+90)
2,155 shares@ US$0.580.8% of flowCommon StockSEC:0001415889-24-021869:0
Canonical exit: 17 Nov 2024 (T+90)
56,061 shares@ US$0.5518.9% of flowCommon StockSEC:0001415889-24-015533:0
300 shares@ US$1.000.1% of flowCommon StockSEC:0001209191-23-058694:0
Canonical exit: 11 Mar 2024 (T+90)
19,123 shares@ US$1.018.5% of flowCommon StockSEC:0001209191-23-057799:0
Canonical exit: 4 Mar 2024 (T+90)
14,378 shares@ US$0.986.1% of flowCommon StockSEC:0001209191-23-057053:0
Canonical exit: 27 Feb 2024 (T+90)
41,026 shares@ US$1.3123.3% of flowCommon StockSEC:0001209191-23-047880:0
Canonical exit: 28 Nov 2023 (T+90)
107,886 shares@ US$1.3262.0% of flowCommon StockSEC:0001209191-23-046402:0
Canonical exit: 13 Nov 2023 (T+90)
71,762 shares@ US$1.2253.3% of flowCommon StockSEC:0001209191-23-045234:0
Canonical exit: 6 Nov 2023 (T+90)
8,000 shares@ US$1.23100.0% of flowCommon StockSEC:0001209191-23-045231:0
Canonical exit: 6 Nov 2023 (T+90)
1,871 shares@ US$0.9832.2% of flowCommon StockSEC:0001209191-23-016507:0
1,640 shares@ US$0.7220.9% of flowCommon StockSEC:0001209191-22-060218:0
1,520 shares@ US$1.6447.0% of flowCommon StockSEC:0001209191-22-049221:0
6,700 shares@ US$2.8632100.0% of flowCommon StockSEC:0001209191-22-035014:0
25 of 52 declarations
About IRulya Therapeutics Inc.
Cortexyme, Inc. is a U.S.-based biopharmaceutical company historically traded on the Nasdaq under the ticker CRTX, in the United States. Importantly, the company changed its corporate name to Quince Therapeutics, Inc. effective August 1, 2022, so recent SEC filings and operating disclosures now generally refer to Quince rather than Cortexyme. The company was founded in 2012 in San Francisco and later established its headquarters in South San Francisco, California. ([ir.quincetx.com](https://ir.quincetx.com/news-releases/news-release-details/cortexyme-appoints-dr-philip-low-its-board-directors?utm_source=openai))
Cortexyme originally built its identity around a differentiated scientific thesis: targeting bacterial pathogens, especially P. gingivalis and gingipains, as potential drivers of neurodegeneration and inflammatory disease progression. That concept shaped its early clinical programs, which focused on small-molecule therapeutics intended for Alzheimer’s disease and other degenerative conditions. Over time, however, the company materially reshaped its strategy. After acquiring Novosteo in 2022 and subsequently divesting its legacy protease inhibitor portfolio in 2023, the business shifted toward a precision-therapeutics model centered on rare skeletal diseases and a novel drug-delivery platform. ([ir.quincetx.com](https://ir.quincetx.com/news-releases/news-release-details/cortexyme-announces-agreement-acquire-novosteo?utm_source=openai))
Read moreShow less
Today, the company is better viewed as a development-stage biotech than as a commercial-stage pharmaceutical company. Its core strategic asset is the AIDE platform, a drug/device combination technology designed to encapsulate a medicine inside the patient’s own red blood cells in order to improve delivery and potentially reduce off-target exposure. The more recent pipeline emphasis is on rare bone disorders, fractures, and adjacent specialty indications. From a competitive standpoint, the company operates in a highly crowded biotech landscape where value creation depends on intellectual property strength, clinical differentiation, regulatory execution, and access to capital. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm?utm_source=openai))
Geographically, the business remains concentrated in the United States, with its operational and research footprint centered in California. As a Nasdaq-listed issuer, it is subject to the disclosure discipline of the U.S. capital markets, including SEC reporting and insider transaction reporting via Form 4, which is relevant for investors tracking management alignment and ownership changes. ([ir.quincetx.com](https://ir.quincetx.com/news-releases/news-release-details/cortexyme-appoints-dr-philip-low-its-board-directors?utm_source=openai))
The most important recent corporate milestones are the name change to Quince Therapeutics, the acquisition of EryDel in 2023, and the disposal of the legacy Cortexyme portfolio. Taken together, these actions signal a clear strategic pivot away from the original Alzheimer’s-focused thesis toward a broader rare-disease platform. For French-speaking investors, the story is therefore one of a small-cap U.S. biotech undergoing a major transformation: high execution risk, limited near-term visibility, but potentially meaningful upside if the new platform advances successfully through the clinic and toward commercialization. ([ir.quincetx.com](https://ir.quincetx.com/static-files/5414b9e4-2eff-49bf-8fa4-1e56d0787d80?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
